title: Prevalence of embolic signals in acute coronary syndromes.
abstract: OBJECTIVE
  The purpose of this study was to assess the prevalence of embolic signals (ES) in acute coronary syndromes (ACS) and their association with stroke.
  
  
  METHODS
  From December 2004 to October 2006, 209 consecutive patients with ACS (without prosthetic heart valves or previous stroke) were studied within 72 hours of symptom onset. Patients underwent ES monitoring in both middle cerebral arteries by transcranial Doppler for 30 minutes. Median follow-up was 14 months after discharge.
  
  
  RESULTS
  Patients were treated according to current European Society Cardiology guidelines. Specifically, 92% of patients received heparin(s), 100% aspirin, 92% clopidogrel, 67% intravenous glycoprotein IIb/IIIa inhibitors, 9% fibrinolysis, and 67% underwent angioplasty. ES were detected in 7 patients (prevalence 3.4%; 95% CI, 1.4 to 6.8). Except for a higher prevalence of ES in patients with unstable angina versus other ACS categories (8.5% versus 1.9%, P=0.047), none of the factors among baseline characteristics, clinical features, ACS treatment, and cardiac findings were associated with the presence of ES. During hospitalization, 3 patients without ES had cerebrovascular events (one stroke and 2 transient ischemic attacks), whereas no cerebrovascular events occurred in patients with ES.
  
  
  CONCLUSIONS
  The prevalence of ES among hospitalized patients with ACS is currently low, possibly because of improvement in ACS treatment. In this ACS sample, ES did not appear associated with short-term risk of cerebrovascular events.
authors.affiliation: INSERM U-698 and Paris-Diderot University, Bichat Hospital, Assistance Publique-Hopitaux de Paris, Paris, France.
authors.forename: Elena
authors.initials: E
authors.lastname: Meseguer
authors.forename: Julien
authors.initials: J
authors.lastname: Labreuche
authors.forename: Cloe
authors.initials: C
authors.lastname: Durdilly
authors.forename: Amaya
authors.initials: A
authors.lastname: Echeverría
authors.forename: Philippa C
authors.initials: PC
authors.lastname: Lavallee
authors.forename: Gregory
authors.initials: G
authors.lastname: Ducrocq
authors.forename: Pierre-Jean
authors.initials: PJ
authors.lastname: Touboul
authors.forename: Philippe Gabriel
authors.initials: PG
authors.lastname: Steg
authors.forename: Pierre
authors.initials: P
authors.lastname: Amarenco
mesh_terms: D054058:Acute Coronary Syndrome / Q000188:drug therapy / Q000453:epidemiology* / Q000503:physiopathology; D000368:Aged; D000789:Angina, Unstable / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology; D015906:Angioplasty, Balloon, Coronary / Q000706:statistics & numerical data; D000925:Anticoagulants / Q000627:therapeutic use; D015897:Comorbidity; D005260:Female; D006801:Humans; D020766:Intracranial Embolism / Q000000981:diagnostic imaging* / Q000453:epidemiology* / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D020768:Middle Cerebral Artery / Q000000981:diagnostic imaging* / Q000503:physiopathology; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D015995:Prevalence; D015912:Thrombolytic Therapy / Q000706:statistics & numerical data; D017585:Ultrasonography, Doppler, Transcranial
chemical_list: D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors